首页> 外文期刊>Archives of Gynecology and Obstetrics >A reappraisal of three-marker (ER/Vim/CEA), four-marker (ER/Vim/CEA/PR), and five-marker (ER/Vim/CEA/PR/p16INK4a) panels in the diagnostic distinction between primary endocervical and endometrial adenocarcinomas in a tissue microarray study
【24h】

A reappraisal of three-marker (ER/Vim/CEA), four-marker (ER/Vim/CEA/PR), and five-marker (ER/Vim/CEA/PR/p16INK4a) panels in the diagnostic distinction between primary endocervical and endometrial adenocarcinomas in a tissue microarray study

机译:重新评估三个标记(ER / Vim / CEA),四个标记(ER / Vim / CEA / PR)和五个标记(ER / Vim / CEA / PR / p16 INK4a )组织微阵列研究中原发性子宫颈癌和子宫内膜腺癌的诊断区别

获取原文
获取原文并翻译 | 示例
       

摘要

Background The choice of appropriate therapeutic plans for primary endocervical adenocarcinomas (ECA) and endometrial adenocarcinomas (EMA) depend on the tumor’s site of origin. The purpose of this study was to compare the performances of the commonly used three-marker (ER/Vim/CEA), four-marker (ER/Vim/CEA/PR) and five-marker (ER/Vim/CEA/PR/p16INK4a) panels in distinguishing between primary ECA and EMA.
机译:背景对于原发性子宫颈癌(ECA)和子宫内膜腺癌(EMA)的合适治疗方案的选择取决于肿瘤的起源部位。这项研究的目的是比较常用的三标记(ER / Vim / CEA),四标记(ER / Vim / CEA / PR)和五标记(ER / Vim / CEA / PR / p16 INK4a )面板来区分主要ECA和EMA。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号